FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334202332> ?p ?o ?g. }

• W2334202332 abstract "BACKGROUND: TMZ is well tolerated with a relatively low incidence of myelotoxicity, which can nonetheless result in treatment delays or death. Our goal was to evaluate risk and validate prediction models in newly diagnosed patients treated with TMZ +/- bevacizumab (BEV). METHODS: Models (from recurrent disease) in newly diagnosed patients (who participated in RTOG 0825) were evaluated. Then independent gender specific models were developed using logistic regression with backward selection (p ≤0.15), to select candidate risk factors . Treatment group (TMZ/placebo or TMZ/BEV) and age were included into the final models as potential confounders. A summary risk score was computed by counting the number of final risk factors that were present. RESULTS: Clinical data from 591 cases was included. Incidence of myelotoxicity was greater in women compared with men (35% versus 15%). Previously published recurrent models did not predict risk in the newly diagnosed patients. For men, the final model included: TMZ/BEV group (OR:1.96;p = 0.04); non-smoker (OR:2.83,p < 0.01); on corticosteroids (OR:1.96;p = 0.09); hemoglobin <13g/dl (OR:2.11, p = 0.04). Patients with risk scores 0-2 were associated with an 8% myelotoxicity risk; scores of 3-5 with 21% risk. For woman, the final model included: KPS≤ 80 (OR:1.78,p = 0.06); incomplete tumor resection (OR:2.57; p = 0.01), BSA < 1.78 (OR:1.99, p = 0.07); age ≥58 yrs (OR:1.76, p = 0.07); BUN < 13 (OR:2.63, p = 0.01); Platelet <313k (OR:2.29; p = 0.02); on non-enzyme inducing anticonvulsants (OR:1.81, p = 0.06) or enzyme inducing anticonvulsants (OR 1.96, p = 0.16), or no anticoagulants (OR:5.87,p = 0.03). Risk score of 1-4 was associated with low risk (13%) while 5-9 was high risk (46%). CONCLUSIONS: TMZ myelotoxicity is a significant clinical issue, and predicting risk should allow treatment optimization. This clinical model suggests that clinical factors can be used to select a group at higher risk. Future work will attempt to improve prediction by inclusion of genetic polymorphisms. Support: -1R01NR013707-01A1, U10CA21661, U10CA180868, U10CA180822, U10 CA37422, U24CA180803 from (NCI), NIH grant- 1R01NR013707-01A1 and Genentech." @default.
• W2334202332 created "2016-06-24" @default.
• W2334202332 creator A5006630838 @default.
• W2334202332 creator A5008238912 @default.
• W2334202332 creator A5012085802 @default.
• W2334202332 creator A5012420674 @default.
• W2334202332 creator A5014074083 @default.
• W2334202332 creator A5016398282 @default.
• W2334202332 creator A5030295108 @default.
• W2334202332 creator A5035101546 @default.
• W2334202332 creator A5036433314 @default.
• W2334202332 creator A5044164887 @default.
• W2334202332 creator A5047066666 @default.
• W2334202332 creator A5060222943 @default.
• W2334202332 creator A5064627876 @default.
• W2334202332 creator A5066158171 @default.
• W2334202332 creator A5089928649 @default.
• W2334202332 creator A5090351388 @default.
• W2334202332 creator A5091435105 @default.
• W2334202332 date "2014-11-01" @default.
• W2334202332 modified "2023-09-26" @default.
• W2334202332 title "CN-21 * RISK MODELING FOR TEMOZOLOMIDE (TMZ)-MYELOTOXICITY IN PATIENTS WITH GLIOBLASTOMA TREATED ON RTOG 0825" @default.
• W2334202332 doi "https://doi.org/10.1093/neuonc/nou243.21" @default.
• W2334202332 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4218016" @default.
• W2334202332 hasPublicationYear "2014" @default.
• W2334202332 type Work @default.
• W2334202332 sameAs 2334202332 @default.
• W2334202332 citedByCount "0" @default.
• W2334202332 crossrefType "journal-article" @default.
• W2334202332 hasAuthorship W2334202332A5006630838 @default.
• W2334202332 hasAuthorship W2334202332A5008238912 @default.
• W2334202332 hasAuthorship W2334202332A5012085802 @default.
• W2334202332 hasAuthorship W2334202332A5012420674 @default.
• W2334202332 hasAuthorship W2334202332A5014074083 @default.
• W2334202332 hasAuthorship W2334202332A5016398282 @default.
• W2334202332 hasAuthorship W2334202332A5030295108 @default.
• W2334202332 hasAuthorship W2334202332A5035101546 @default.
• W2334202332 hasAuthorship W2334202332A5036433314 @default.
• W2334202332 hasAuthorship W2334202332A5044164887 @default.
• W2334202332 hasAuthorship W2334202332A5047066666 @default.
• W2334202332 hasAuthorship W2334202332A5060222943 @default.
• W2334202332 hasAuthorship W2334202332A5064627876 @default.
• W2334202332 hasAuthorship W2334202332A5066158171 @default.
• W2334202332 hasAuthorship W2334202332A5089928649 @default.
• W2334202332 hasAuthorship W2334202332A5090351388 @default.
• W2334202332 hasAuthorship W2334202332A5091435105 @default.
• W2334202332 hasBestOaLocation W23342023321 @default.
• W2334202332 hasConcept C120665830 @default.
• W2334202332 hasConcept C121332964 @default.
• W2334202332 hasConcept C126322002 @default.
• W2334202332 hasConcept C141071460 @default.
• W2334202332 hasConcept C142724271 @default.
• W2334202332 hasConcept C143998085 @default.
• W2334202332 hasConcept C151956035 @default.
• W2334202332 hasConcept C204787440 @default.
• W2334202332 hasConcept C27081682 @default.
• W2334202332 hasConcept C2776194525 @default.
• W2334202332 hasConcept C2776694085 @default.
• W2334202332 hasConcept C2777389519 @default.
• W2334202332 hasConcept C2777802072 @default.
• W2334202332 hasConcept C502942594 @default.
• W2334202332 hasConcept C50382708 @default.
• W2334202332 hasConcept C61511704 @default.
• W2334202332 hasConcept C71924100 @default.
• W2334202332 hasConcept C77350462 @default.
• W2334202332 hasConceptScore W2334202332C120665830 @default.
• W2334202332 hasConceptScore W2334202332C121332964 @default.
• W2334202332 hasConceptScore W2334202332C126322002 @default.
• W2334202332 hasConceptScore W2334202332C141071460 @default.
• W2334202332 hasConceptScore W2334202332C142724271 @default.
• W2334202332 hasConceptScore W2334202332C143998085 @default.
• W2334202332 hasConceptScore W2334202332C151956035 @default.
• W2334202332 hasConceptScore W2334202332C204787440 @default.
• W2334202332 hasConceptScore W2334202332C27081682 @default.
• W2334202332 hasConceptScore W2334202332C2776194525 @default.
• W2334202332 hasConceptScore W2334202332C2776694085 @default.
• W2334202332 hasConceptScore W2334202332C2777389519 @default.
• W2334202332 hasConceptScore W2334202332C2777802072 @default.
• W2334202332 hasConceptScore W2334202332C502942594 @default.
• W2334202332 hasConceptScore W2334202332C50382708 @default.
• W2334202332 hasConceptScore W2334202332C61511704 @default.
• W2334202332 hasConceptScore W2334202332C71924100 @default.
• W2334202332 hasConceptScore W2334202332C77350462 @default.
• W2334202332 hasLocation W23342023321 @default.
• W2334202332 hasLocation W23342023322 @default.
• W2334202332 hasOpenAccess W2334202332 @default.
• W2334202332 hasPrimaryLocation W23342023321 @default.
• W2334202332 hasRelatedWork W1982473272 @default.
• W2334202332 hasRelatedWork W1999901911 @default.
• W2334202332 hasRelatedWork W2107813339 @default.
• W2334202332 hasRelatedWork W2109477721 @default.
• W2334202332 hasRelatedWork W2117074807 @default.
• W2334202332 hasRelatedWork W2162386068 @default.
• W2334202332 hasRelatedWork W2190171800 @default.
• W2334202332 hasRelatedWork W2316207646 @default.
• W2334202332 hasRelatedWork W2412140884 @default.
• W2334202332 hasRelatedWork W2469912817 @default.
• W2334202332 hasRelatedWork W2544634021 @default.
• W2334202332 hasRelatedWork W2553279539 @default.
• W2334202332 hasRelatedWork W2563270382 @default.

• next